Novo Nordisk (ADR)
Develops GLP-1 and insulin medicines for diabetes, obesity and rare diseases.
$45.60
After-hours close+0.00 (+0.00%)
At close$45.60(−1.43%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.80 | — | — |
| Aug 2026 | $0.82 | $0.96 | +17.1% |
| May 2026 | $0.87 | $1.04 | +19.5% |
| Feb 2026 | $0.90 | $1.00 | +11.1% |
| Nov 2025 | $0.77 | $1.02 | +32.5% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Jan 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Oct 2016 | |||
| Aug 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | $0.80 | — | — | $11.22B | — | — |
| Aug 5, 2026 | $0.82 | $0.96 | +17.1% | $10.89B | $12.13B | +11.3% |
| May 6, 2026 | $0.87 | $1.04 | +19.5% | $10.86B | $11.02B | +1.5% |
| Feb 3, 2026 | $0.90 | $1.00 | +11.1% | $12.13B | $12.50B | +3.1% |
| Nov 5, 2025 | $0.77 | $1.02 | +32.5% | $12.37B | $11.78B | −4.8% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 6, 2025 | ||||||
| May 7, 2025 | ||||||
| Feb 5, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 7, 2024 | ||||||
| May 2, 2024 | ||||||
| Jan 31, 2024 | ||||||
| Nov 2, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 4, 2023 | ||||||
| Feb 1, 2023 | ||||||
| Nov 2, 2022 | ||||||
| Aug 3, 2022 | ||||||
| Apr 29, 2022 | ||||||
| Feb 2, 2022 | ||||||
| Nov 3, 2021 | ||||||
| Aug 4, 2021 | ||||||
| May 5, 2021 | ||||||
| Feb 3, 2021 | ||||||
| Oct 30, 2020 | ||||||
| Aug 6, 2020 | ||||||
| May 6, 2020 | ||||||
| Feb 5, 2020 | ||||||
| Nov 1, 2019 | ||||||
| Aug 9, 2019 | ||||||
| May 3, 2019 | ||||||
| Feb 1, 2019 | ||||||
| Nov 1, 2018 | ||||||
| Aug 8, 2018 | ||||||
| May 2, 2018 | ||||||
| Feb 1, 2018 | ||||||
| Nov 1, 2017 | ||||||
| Aug 10, 2017 | ||||||
| May 3, 2017 | ||||||
| Feb 2, 2017 | ||||||
| Oct 28, 2016 | ||||||
| Aug 5, 2016 | ||||||
| Apr 29, 2016 | ||||||
| Feb 3, 2016 | ||||||
| Oct 29, 2015 | ||||||
| Aug 6, 2015 | ||||||